Baolingbao Biology Co Ltd - Asset Resilience Ratio
Baolingbao Biology Co Ltd (002286) has an Asset Resilience Ratio of 0.07% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Baolingbao Biology Co Ltd (002286) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Baolingbao Biology Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Baolingbao Biology Co Ltd asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Baolingbao Biology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Baolingbao Biology Co Ltd to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.00 Million | 0.07% |
| Total Liquid Assets | CN¥2.00 Million | 0.07% |
Asset Resilience Insights
- Limited Liquidity: Baolingbao Biology Co Ltd maintains only 0.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Baolingbao Biology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Baolingbao Biology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 23.94% |
|
ChemPartner PharmaTech Co Ltd
SHE:300149 |
Biotechnology | 1.67% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653 |
Biotechnology | 59.25% |
Annual Asset Resilience Ratio for Baolingbao Biology Co Ltd (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Baolingbao Biology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.10% | CN¥2.80 Million ≈ $409.73K |
CN¥2.78 Billion ≈ $407.01 Million |
+0.87pp |
| 2023-12-31 | -0.77% | CN¥-20.42 Million ≈ $-2.99 Million |
CN¥2.66 Billion ≈ $389.08 Million |
-4.29pp |
| 2021-12-31 | 3.52% | CN¥106.67 Million ≈ $15.61 Million |
CN¥3.03 Billion ≈ $443.24 Million |
+3.73pp |
| 2020-12-31 | -0.21% | CN¥-5.48 Million ≈ $-802.34K |
CN¥2.62 Billion ≈ $382.76 Million |
+0.09pp |
| 2019-12-31 | -0.30% | CN¥-7.62 Million ≈ $-1.12 Million |
CN¥2.52 Billion ≈ $368.57 Million |
+0.10pp |
| 2018-12-31 | -0.41% | CN¥-10.51 Million ≈ $-1.54 Million |
CN¥2.58 Billion ≈ $377.43 Million |
-0.29pp |
| 2017-12-31 | -0.12% | CN¥-2.44 Million ≈ $-357.60K |
CN¥2.11 Billion ≈ $308.31 Million |
0.00pp |
| 2016-12-31 | -0.11% | CN¥-2.15 Million ≈ $-314.40K |
CN¥1.93 Billion ≈ $282.65 Million |
-0.02pp |
| 2015-12-31 | -0.09% | CN¥-1.81 Million ≈ $-265.48K |
CN¥1.91 Billion ≈ $280.01 Million |
+0.01pp |
| 2014-12-31 | -0.11% | CN¥-1.91 Million ≈ $-279.19K |
CN¥1.77 Billion ≈ $258.44 Million |
+0.01pp |
| 2013-12-31 | -0.12% | CN¥-2.00 Million ≈ $-292.89K |
CN¥1.68 Billion ≈ $245.28 Million |
-- |
About Baolingbao Biology Co Ltd
Baolingbao Biology Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of functional sugar in China and internationally. The company offers prebiotics, including galacto-oligosaccharides, isomaltooligosaccharides, fructooligosaccharides, and xylooligosaccharides; sugar alcohols and sources, such as erythritol, trehalose, crystallized fructose, a… Read more